Fate and J&J end deal that once promised $3B in mile­stones; biotech cuts staff

Fate Ther­a­peu­tics said that it agreed with John­son & John­son to ter­mi­nate a part­ner­ship they struck in 2020 to de­vel­op can­cer im­munother­a­pies, a deal that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.